Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Long-Term Investments (2021 - 2025)

SAB Biotherapeutics' Long-Term Investments history spans 3 years, with the latest figure at $46.9 million for Q4 2025.

  • For Q4 2025, Long-Term Investments changed N/A year-over-year to $46.9 million; the TTM value through Dec 2025 reached $46.9 million, changed N/A, while the annual FY2025 figure was $46.9 million, N/A changed from the prior year.
  • Long-Term Investments reached $46.9 million in Q4 2025 per SABSW's latest filing, down from $50.6 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $116.2 million in Q3 2021 to a low of $1.2 million in Q1 2024.
  • Average Long-Term Investments over 3 years is $74.5 million, with a median of $83.4 million recorded in 2021.